🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I’ve handled the review of > 1000 papers at @nature. Over time, you notice aspects of presentation on which reviewers tend to comment. In the interests of minimizing hassles during review, I offer the following suggestions (a bit targeted to climate papers).

So proud of the brilliant Hayoung Choi highlighted as one of this months emerging investigators in ATS Blue Journal for his work in bronchiectasis 👏👏👏👏👏👏

#WBConf24 📊 Do you have a scientific work on #AATD #Bronchiectasis #NTM #PCD #RespiratoryInfections #RespiratoryPhysiotherapy ? This is your chance to submit it! check guidelines & topics➡️world-bronchiectasis-conference.org/2024/?page_id=… ⏰Deadline: 29 March 2024 📅4-6 July 2024 🌍Dundee, Scotland

The latest in the EMBARC ‘Lessons in Bronchiectasis’ series will discuss the association of bronchiectasis and other airway diseases. 📆 20 March, 2024 ⏰ 14:00–15:00 CET 💻 Online Register for free, and access recordings from previous sessions: bit.ly/4c4X5PW

#WBConf24 👀 Interested in learning more about paediatric bronchiectasis? 📌 Join us saturday morning and attend the track See the full programme here - world-bronchiectasis-conference.org/2024/?page_id=… 📅 4-6 July 2024 🌍 Dundee, Scotland #PaediatricBronchiectasis

Excited to share our new paper in ATS Blue Journal describing the detailed microbiology and immunology of bronchiectasis exacerbations We show - Viruses are a major cause (particularly rhinovirus) - There are exacerbation subtypes (neutrophilic/eosinophilic) atsjournals.org/doi/abs/10.116…

Over the moon to have been selected as one of the Rising Stars of #WBConf24 🫁 Looking forward to presenting my research on #eosinophils in #bronchiectasis in July😊

Excited to share our new paper ATS Blue Journal A potential new treatment for bronchiectasis: an antibody therapy against P.aeruginosa Work led by Merete Long in collaboration with AstraZeneca Work underpins the GREAT-2 trial: ISRCTN70034823 now enrolling atsjournals.org/doi/epdf/10.11…

Big news for bronchiectasis! The phase 3 ASPEN trial of Brensocatib is POSITIVE with a reduction in exacerbations, and important effects on symptoms and slowing rate of lung function decline at the 25mg dose. investor.insmed.com/2024-05-28-Ins… A new anti-inflammatory therapy 🧵 Insmed

Loves it!

#WBConf24 📍Join us in-person in Dundee at the Dalhousie building or connect virtually to the livestream ➡️Register now!- world-bronchiectasis-conference.org/2024/?page_id=… 📅 4-6 July 2024 🌍 Dundee, Scotland

🚀One Week to Go! #WBConf24 is almost here! Have you secured your place?✔️ The final Programme is available now. Explore the schedule, plan your sessions and get ready for expert insights and networking. 🌐world-bronchiectasis-conference.org/2024/ 🗓️ 4-6 July 2024 📍 Dundee, Scotland

Excited to go back to Dundee for this fantastic conference and reunite with friends and colleagues!

It was a great honor to be introduced as an emerging investigator in the Blue Journal. Special thanks to my mentor, Professor James Chalmers, for his insightful guidance, and to my colleagues in Dundee.

The Blue Journal thanks Yonghua Gao, MD, PhD, for his contribution to the July 1 issue Endotypes of Exacerbation in Bronchiectasis: An Observational Cohort Study Yonghua Gao James D Chalmers atsjournals.org/doi/full/10.11…

A respected leader and legend in bronchiectasis. Proud to have learned with you.

Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study - The Lancet Respiratory Medicine thelancet.com/journals/lanre…

What’s this Department of Government Efficiency thing people keep talking about? Personally, I’ve never heard of it 🤷‍♂️

brian lipworth Eric Topol Science Magazine ERS publications Interestingly, we could see this (small airway/gas exchange problems) using #xenon #MRI bit.ly/42uia1J

We did it! Absolutely thrilled to share the results of the ASPEN trial published today in NEJM Brensocatib(10mg and 25mg vs placebo) reduced exacerbations over 52 weeks and slowed lung function decline A new treatment for bronchiectasis patients nej.md/4lBHwUr